Drug Discovery World - Pharma, Drug Development, Therapeutics, Chemistry-logo

Drug Discovery World - Pharma, Drug Development, Therapeutics, Chemistry

Science Podcasts >

More Information


United Kingdom






Drug Discovery In The Age Of Big Data – The Impact Of RNAi & CRISPR/Cas9 Technologies

This episode discusses how RNA interference and CRISPR/Cas9 technologies are helping to build better mouse models and push drug discovery into a new era. Most, if not all, consumers are feeling the weight of rising drug costs. But while much of the controversy surrounding rising drug prices has focused on a handful of pharmaceutical companies that have snapped up old drugs and then aggressively raised prices, the fact is that drug prices are far more likely to further increase due to the...


Phenotypic Screening - Advancing The Science From Discovery To Regulatory Science

Phenotypic screening is transforming drug discovery as advances are made in development of human-based physiologically-relevant in vitro systems. Integration of phenotypic drug discovery approaches with target-based screening can improve success rates as assays can be leveraged for the discovery of novel mechanisms and for building knowledge of disease biology. The article was written by Dr Ellen L. Berg who is Chief Scientific Officer at DiscoverX If you'd like to view the original...


UX Design - Maximising The Value Of Scientific Software In Life Science R&D

Using scientific software can be frustrating and time-consuming, resulting in less productive research. This episode aims to demonstrate that User Experience (UX) Design – an evidence-based design process that centres on the behaviours and needs of users – offers specific efficiency benefits for life science R&D. Already well-established in other industries, such as retail and finance, UX design holds great unlocked potential for scientific software design. Because it offers a clear path...


Spheroids - Rapidly Becoming A Preferred 3D Culture Format

There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture. Scaffold-free 3D culture systems that generate spheroids (and other similar multicellular aggregations) have proved useful as they offer an easy route to access 3D culture and transition into plate-based higher throughput. The emergence of ultra-low attachment (ULA) or cell-repellent plates that generate spheroids has been a major factor in...


The Discoverome - Creative Destruction of Barriers for Faster to Patient Medicines R&D

Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast. What is needed is not just new assays, technology and ideas. It is new organisations, influencers and shared working. A generation Y approach for generation Y times. The shape of medicines R&D has transformed. Much like the story of Hollywood studies but at an alarming rate, the industry...


Fusion Therapy - A New Approach to Combining Treatments

Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for new ways to enhance treatment effect and tolerability. New fusion technology molecules appear to offer a beneficial synergy, but will this withstand clinical investigation and what is its future potential? The use of systemic chemotherapy for the treatment of haematological malignancies and solid tumours...


Breath based biomarker detection - Informing drug development and future treatment regimes

The recent approval of the first liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of precision medicine-based drug treatment regimes. Precision medicine allows detailed insights into the disease processes that underlie clinical disease. This field has first started with genetics, and genetic mutation-based models that can predict disease state such as tumour phenotype or likely...


3D Cell Culture: A Rapidly Emerging Technique for Drug Discovery

The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease. In this episode, we discuss: 3D cell culture in drug discovery; advances in hydrogels and scaffolds for creation of spheroids and organoids; a novel approach to cell therapy; what the future may hold: bioprinting and organ-on-chip; and...


Blockchain Technology in Drug Discovery: Use-Cases in R&D

There is no doubt that the interest and hype around blockchain or distributed ledger technology (DLT) builds daily. The explosion of articles and books recently is testament to this. But what is a blockchain and how might DLT impact drug discovery, healthcare, Pharma and R&D? The 7 higher level blockchain use-cases in drug discovery R&D discussed in this episode are: Patents and Intellectual Property (IP); Genomic data management; Raw and refined research data; Collaboration; Clinical...


Epigenetics - Unlocking the potential for personalised medicine

Epigenetic factors are rapidly taking the spotlight as major players in the critical pathways that trigger the onset and progression of numerous life-threatening and debilitating genetic diseases. Technologies that harness our growing knowledge of epigenetic mechanisms look set to revolutionise approaches to medicine and healthcare across the globe. In this episode 'Epigenetics - Unlocking the potential for personalised medicine', we discuss: Methylation matters – the importance of DNA...


Nanomedicines - Exploring the past, present and future

Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines. In this episode we explore nanomedicines past, present and future and their role in drug discovery and development. The original article this episode is based on was written by Professor Yvonne Perrie & Dr Euan Ramsay. If you'd like to view the original article then follow the...


Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine (Part 2)

In this episode, part 2 that is continued from the previous episode, we discuss: Process chemistry/route selection; Drug metabolism: the case of cytochrome; Metalloporphyrins as chemical mimics of cytochrome P-450 systems; Diversified analogues through automated oxidation chemistry; Precision Medicine; Precision versus Personalised Medicine; Alzheimer’s Disease – a case study in precision medicine; Translational chemical and systems biology drug discovery; Translational chemical biology –...


Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine (Part 1)

In this episode we discuss: current drug approvals; translational chemical biology – the knowledge deficit; reverse pharmacology observational therapeutics; renaissance of plant-based natural products; expanding chemical space; hybrid molecules; flow chemistry and chemoinformatics. The original article this episode is based on was written by Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu. If you'd like to view the original article...


Monitoring the balance between immune repression and stimulation in cancer immunotherapy

Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies. By weaponising the body’s own immune defences, these drugs have shown great promise in clinical trials and are now experiencing significant commercial success. In this episode, we discuss: active immunotherapies, passive immunotherapies, using biomarkers to monitor the immune sytem, and a new autoantibody profiling tool...


Pharma Derisking - Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition

Derisking is the intelligent application of early in vitro testing to investigate areas of major risk for a new molecule in development, helping to avoid spending time and resource on a compound that may carry with it a high potential liability of nonapproval or market withdrawal. Derisking provides information that allows for more informed decision-making in the high-risk arena of drug development. In this episode, we explore how intelligent application of early in vitro testing, can...


Filling The Drug Discovery Abyss - Novel Business Models to Push Through The Valley of Death

In this episode, we explore different novel business models to solve this problem of developing new drugs, we discuss The Harrington Project, Milner Therapeutics Institute, the Tri-Institutional Therapeutics Discovery Institute, as examples of strategic arrangements, before finally concluding. The original article this episode is based on was written by Dr Swati Prasad, Dr Charles McOsker, Professor Kathryn Chapman and Dr Michael Foley. If you'd like to view the original article then...


Adopting Artificial Intelligence (AI) is Essential for a Sustainable Pharma Industry

In this episode, we explore how artificial intelligence (AI) can transform the scientific method and, in turn, the pharmaceutical industry. We discuss the barriers to drug development, AI’s role, and finally how embracing technology can revolutionise the drug discovery process. The original article this episode is based on was written by Professor Jackie Hunter. If you'd like to view the original article then follow the link...


21st Century Drug Discovery - A Strategic Vision (Part 2)

In this episode (part 2), we begin by discussing where we are now, we then talk about rational design and iterative discovery in a modern world, the model: nuclei or electrons, testing and effective use of time and technologies, the future, before finally presenting our strategic vision for 21st century drug discovery. The original article this episode is based on was written by Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant. If you'd...


21st Century Drug Discovery - A Strategic Vision (Part 1)

In this episode (part 1), we give a brief history of drug discovery, discuss the 1980’s and the shift in approach, the effects of the new approach, recent approaches to improve return, chemistry, and fragment based lead discovery. The original article this episode is based on was written by Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant. If you'd like to view the original article then follow the link...


The rise of immunotherapies – Strategies to accelerate their advance into clinical trials.

Immunotherapies are a new class of drug that harnesses the potential of the body’s immune system to target and destroy tumours. The episode is about the rise of immunotherapies. In the episode we discuss: how the rise of immunotherapies in the past decade has had a transformative effect on the prospects for the treatment of patients with cancer; a brief history of immunotherapies; preclinical safety assessments of novel immunotherapies; assessing antibody binding using tissue...


Try Premium for 30 days

Live games for all NFL, MLB, NBA, & NHL teams
Commercial-Free Music
No Display Ads